SOCS3 and cancer: Additionally, in triple-negative breast cancer cells, PEGylated SOCS3 mimetics encapsulated into PLGA nanoparticles have been shown to act as selective inhibitors of the JAK/STAT pathway, effectively reducing STAT3 phosphorylation, and suggesting a potential therapeutic approach for cancers with dysregulated JAK/STAT signaling (50).